Document is current
Any future updates will be listed below
-
Authors
Newell, Felicity https://orcid.org/0000-0003-0469-2705
Wilmott, James S.
Johansson, Peter A.
Nones, Katia
Addala, Venkateswar https://orcid.org/0000-0002-3569-2065
Mukhopadhyay, Pamela
Broit, Natasa https://orcid.org/0000-0001-8490-5437
Amato, Carol M. https://orcid.org/0000-0002-4945-8819
Van Gulick, Robert
Kazakoff, Stephen H. https://orcid.org/0000-0001-6562-1383
Patch, Ann-Marie https://orcid.org/0000-0001-6121-4019
Koufariotis, Lambros T.
Lakis, Vanessa
Leonard, Conrad https://orcid.org/0000-0002-4131-2065
Wood, Scott https://orcid.org/0000-0003-4543-8850
Holmes, Oliver
Xu, Qinying
Lewis, Karl
Medina, Theresa
Gonzalez, Rene
Saw, Robyn P. M. https://orcid.org/0000-0002-3354-806X
Spillane, Andrew J. https://orcid.org/0000-0002-8354-434X
Stretch, Jonathan R.
Rawson, Robert V.
Ferguson, Peter M.
Dodds, Tristan J.
Thompson, John F. https://orcid.org/0000-0002-2816-2496
Long, Georgina V. https://orcid.org/0000-0001-8894-3545
Levesque, Mitchell P.
Robinson, William A.
Pearson, John V.
Mann, Graham J.
Scolyer, Richard A. https://orcid.org/0000-0002-8991-0013
Waddell, Nicola https://orcid.org/0000-0002-3950-2476
Hayward, Nicholas K. https://orcid.org/0000-0003-4760-1033
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1111678, 1139071, APP1139071, 1117663)
Deborah and John McMurtrie MIA Pathology Fellowship
Jani Haenke Melanoma Pathology Fellowship
University of Sydney Medical Foundation
Melanoma Institute Australia New South Wales Health Pathology Royal Prince Alfred Hospital
- License Information
-
More Information
Article History
Received: 31 March 2020
Accepted: 24 September 2020
First Online: 16 October 2020
Competing interests
: J.V.P. and N.W. are founders and shareholders of genomiQa Pty Ltd, and members of its Board. R.A.S. has received fees for professional services from Merck Sharp & Dohme, GlaxoSmithKline Australia, Bristol-Myers Squibb, Dermpedia, Novartis Pharmaceuticals Australia Pty Ltd, Myriad, NeraCare and Amgen. G.V.L is consultant advisor for Aduro, Amgen, Array, BMS, MERCK MSD, Novartis, Pierre-Fabre, Roche, Sandoz. R.P.M.S has participated in advisory boards for MSD, Novartis and received speaking honoraria from BMS. J.F.T. has received honoraria for advisory board participation from Merck Sharpe Dohme Australia and Bristol Myers Squibb Australia. J.F.T. has also received honoraria and travel expenses from GSK and Provectus Inc. The remaining authors declare no competing interests.
